Kornimate/medical-research-clean huggingface dataset:
pulmonary artery harmonic ace+7 energy sealing in open lobectomy

Conditions: Lung Cancer

Summary: vats anatomical lung resection provides an effective minimally invasive treatment strategy for stage i and ii lung cancer. vats lobectomy is associated with significantly less postoperative atrial fibrillation, blood transfusion, renal failure, and other complications when compared with lobectomy via thoracotomy. although vats lobectomy has been proven to be effective and safe in experienced hands, it is not devoid of risk. intra-operative surgical complications can be at times catastrophic. complications include: pulmonary vascular injuries (pa, pulmonary vein) necessitating urgent conversion to open thoracotomy and even death14. causes of conversion included pa injury, difficult anatomy, bulky/calcified lymph nodes, and technical problems including stapler misfire. pa injury alone constituted 37.5% of all conversions. proper dissection of all tissue around pa branches is sometime difficult especially in the presence of adhesions or large, calcified lymph nodes and may increase the risk of vascular injury. currently, in spite of being a safe and effective technique in experienced hands, a minority of anatomical pulmonary resections are being performed by vats. in an analysis utilizing the nationwide inpatient sample (nis) database in the united states, only 15% of anatomical lung resections were performed by vats. the technical difficulty and danger of vats lobectomy is directly related to pa branch manipulation, stapling and division. pa manipulation is the main hesitation of many thoracic surgeons regarding the adoption of vats lobectomy. the investigators believe that by decreasing the manipulation and dissection required by the surgeon on the pa branches, these procedures will be safe and therefore more prevalent for anatomical pulmonary resections.

this study consists in a pilot study evaluating the feasibility of energy sealing lobar pa branches for lobectomy in humans. all patients planned to undergo an open lobectomy at the chum - hôpital notre-dame will be approached in an attempt to enroll them in the pilot study. in the investigator's institution, lobectomies are either done open (thoracotomy) or by minimally invasive approach, known as vats (video assisted thoracoscopic surgery). this decision is based on the surgeon, tumor size, tumor localization and patient characteristics. only patients already planned for an open lobectomy will be approached. potential patients will be identified by going over the operation request forms. patients booked for an open lobectomy will be approached either in the preoperative clinic or the day before surgery, when admitted. goal is to recruit 10 patients.

Eligibility criteria:
inclusion criteria: * all patients planned to undergo an open lobectomy at the chum-hôpital notre-dame exclusion criteria: * age \< 18 years old * inability to consent to the study

Keywords: vats energy sealing
long-term outcome of her2-amplified metastatic breast cancer: a retrospective analysis

Conditions: ERBB2; Breast Cancer; Metastatic Neoplasm

Summary: the aim of this study is to analyze cases of human epidermal growth factor receptor (her) 2-positive metastatic breast cancer (mbc) of the last 10 years at the university hospital of zurich to assess the efficacy of the treatment with trastuzumab in her2-positive mbc and to find out associations between different variables and the outcome. the aim is to find out probable prognostic factors and patterns of disease progression. prognostic factors could optimize treatment approaches and result in a delay of disease progression.

human epidermal growth factor (her2) is a receptor tyrosine kinase and regulates diverse functions in normal cells such as growth, differentiation and survival of cells. in 25-30 per cent of breast cancer her2 gene is amplified, what result in abnormally high levels of encoded her2 protein in malignant cells. overexpression or amplification of her2 is associated with an aggressive form of breast cancer seen by significantly shortened disease-free survival and overall survival. trastuzumab, a humanized monoclonal antibody against the extracellular domain of her2, inhibits the growth of breast tumor cells by receptor internalization, inhibition of cell-cycle progression and recruitment of immune-effector cells. trastuzumab, as the first anti-her2 therapy, is approved since 1998 in the united states and since 2000 in european countries for the treatment of her2-overexpressing metastatic breast cancer (mbc). single therapy as well as combination with chemotherapy has significantly improved the outcome of these women. shown by longer time to disease progression, longer duration of response, lower rate of death at 1 year, longer survival and a 20 per cent reduction in the risk of death. but still is little known about the long-term outcome nor patterns of disease progression of her2-positive mbc. a few case reports showed a prolonged complete remission in her2-positive mbc under an anti-her2 treatment (trastuzumab, t-dm1, pertuzumab). these cases had some common characteristics such as negative hormone receptor status and metastasis to the live. another hypothesis is a worse prognosis for patients with early development of cns metastases.

Eligibility criteria:
inclusion criteria: * received at least 1 dose of trastuzumab in metastatic setting at the university hospital of zurich from 01/2004 to 12/2014. * her2+ status confirmed by immunohistochemistry (ihc) 3+ or fluorescence in situ hybridization (fish) ≥ 2. exclusion criteria: -
research study to investigate how well semaglutide works in people living with heart failure and obesity

Conditions: Obesity

Summary: this study will look at how the participants daily life is affected by their heart failure. the study will also look at the change in participants body weight from the start to the end of the study. this is to compare the effect on heart failure symptoms and on body weight in people taking semaglutide (a new medicine) to people taking "dummy" medicine. participants will either get semaglutide or "dummy" medicine - which treatment participants get is decided by chance. participants will need to take 1 injection once a week. the study medicine is injected with a thin needle in a skin fold in the stomach area, thigh or upper arm. during the study participants will have talks with the study staff about healthy lifestyle choices including healthy food and physical activity. the study will last for approximately 59 weeks. participants will have 11 clinic visits and 1 phone call with the study doctor. women: women cannot take part if they are pregnant, breast-feeding or plan to become pregnant during the study period.


Eligibility criteria:
inclusion criteria: * male or female, age above or equal to 18 years at the time of signing informed consent. * body mass index (bmi) greater than or equal to 30.0 kg/m\^2 * new york heart association (nyha) class ii-iv * left ventricular ejection fraction (lvef) greater than or equal to 45 percentage at screening exclusion criteria: * a self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records * haemoglobin a1c (hba1c) greater than or equal to 6.5 percentage (48 mmol/mol) based on latest available value from medical records, no older than 3 months or if unavailable a local measurement at screening
evaluation of memantine versus placebo on ischemic stroke outcome

Conditions: Ischemic Stroke; Excitotoxicity; Memantine

Summary: the researchers aim to investigate the effect of memantine on stroke outcome in a randomized double-blind placebo-controlled clinical trial.


Eligibility criteria:
inclusion criteria: * presentation at first 24hrs of disease onset * confirmation of ischemic stroke in mca territory by imaging. * accepted consent form exclusion criteria: * allergy history to memantine * stage 4 -5 renal failure base on acute kidney injury network criteria * moderate to severe hepatic failure (child-pugh criteria, grade b and c) * history of epilepsy * history of dementia * history of memantine use in recent 6 months * pregnancy or breastfeeding * severe drug adverse effects
survival and predictive factors of clinical outcome in patients with acquired brain injury

Conditions: Acquired Brain Injury

Summary: the prediction of the final neurological and functional status of patients with acquired brain injury remains very uncertain despite the findings of current medicine. the aim of the study is to evaluate the clinical outcomes in patients with the most severe degree of brain injury hospitalized in the long-term intensive care unit of the military university hospital prague.

the prediction of the final neurological and functional status of patients with acquired brain injury remains very uncertain despite the findings of current medicine. current medical knowledge is particularly limited in patients with the most severe brain injury who had to be tracheostomized and admitted to long-term intensive care unit. in the czech republic, there is a complete lack of data on clinical outcomes in these patients. some recent studies has not confirmed the long-standing better outcome in patients with traumatic brain injury compared to non-traumatic etiologies. the aim of the study is to evaluate the clinical outcomes in patients with the most severe degree of brain injury hospitalized in the long-term intensive care unit of the military university hospital prague.

Eligibility criteria:
inclusion criteria: * acquired brain injury * initial glasgow coma scale (gcs) score less than 8 points * tracheostomy for persistent impairment of consciousness exclusion criteria: * none

Keywords: acquired brain injury consciousness disorders prognosis persistent vegetative state
a comparison of netspot imaging versus f-fdg-pet in head and neck cancer patients

Conditions: Head and Neck Squamous Cell Carcinoma

Summary: this is a proof-of-concept trial to compare 18f-fdg-pet/ct with netspot (68ga-dota-tate), a commercially available radiotracer packet that utilizes 68ga to image sstr-specific tissue.

patients meeting inclusion criteria will be consented at the time of scheduling. all patients will undergo 18f-fdg-pet/ct per established protocol. following 18f-fdg-pet/ct, the patient will undergo netspot imaging with the aaa-provided dose. these scans will be performed no less than 8 hours, no more than 7 days apart. for patients undergoing same-day imaging, netspot imaging will be performed prior to 18f-fdg-pet/ct. following imaging, both 18f-fdg-pet/ct and netspot imaging will be compared by trained neuroradiologists for suv values and concordance with known sites of disease. biopsies will be performed as is standard to verify all sites of primary or metastatic disease. patients with oropharyngeal tumors will have hpv testing performed via the standard of care surrogate marker p16. patients with p16-positive tumors will be recorded and analyzed separately for the above measures. patients will be followed for a total of 1 year after the study and outcomes of overall survival, disease-free survival, presence and site of recurrence and development of metastatic disease will be recorded. all gathered data will be compared between reported 18f-fdg-pet/ct and netspot imaging for true positive, true negative, positive predictive value and negative predictive value of patient groups.

Eligibility criteria:
inclusion criteria: patients with suspected or diagnosed hnscc undergoing planned 18f fdg pet/ct at the time of primary diagnosis or after completion of treatment. exclusion criteria: inability to undergo 18f-fdg-pet/ct imaging due to medical comorbidities
observational comparison of tooth-borne, bone-borne and hybrid distraction following sarpe.

Conditions: Malocclusion

Summary: the investigators will perform a prospective, non-randomized observational study. the aim of this study is to evaluate stability of tooth-borne, bone-borne and hybrid expansion following sarpe by using data collected according to the existing sarpe follow-up protocol. the insights of this study might elucidate the preferred expansion technique and improve surgical technique.

maxillary transverse discrepancy (mtd) is a difficult deformity to correct. in skeletal immature patients, an orthopedic-orthodontic expansion is the preferred treatment strategy. in case of a skeletal mature patient, a surgical treatment should be considered. a surgically assisted rapid palatal expansion (sarpe) procedure is a common surgical treatment for mtd in skeletal mature patients. in this procedure the skeletally mature, maxillary sutures are surgically reopened. one week postoperatively, the patient will activate the expander appliance. there are three widely-used expander appliances: tooth-borne, bone-borne and hybrid expanders. the use of the expander appliance is based on surgeon and referring orthodontist's common practice and preference. a tooth-borne expander is an appliance which is supported by the teeth and bridges the palate. a bone-borne expander is surgically placed at the level of the palate during sarpe surgery. hybrid expansion is a combination of tooth-borne and bone-borne expansion. these appliances progressively widen the maxilla by daily activation of the distractor. the activation is stopped when the surgeon and/or referring orthodontist judge that the maxilla is sufficiently expanded. however, historical research with the use of cast model's and 2d posteroanterior cephalograms suggest that this expansion is not stable. with the emergence of 3d cone-beam computed tomography (cbct) and its appliance as standard of care for pre-operative diagnosis and postoperative follow-up, stability and complications can be assessed more accurately. the goal of this study is to prospectively evaluate stability following sarpe, by analyzing the clinical and radiological data collected according to the existing clinical sarpe follow-up protocol. the secondary outcome is to evaluate complications following the three distractors.

Eligibility criteria:
inclusion criteria: * maxillary transverse discrepancy * skeletal mature patients * sarpe treatment is indicated exclusion criteria: * patients with a syndrome with an influence on head-and-neck morphology (such as apert, crouzon syndrome) * cleft patients

Keywords: sarpe distraction osteogenesis transverse maxillary hypoplasia
fmt delivered by capsule versus colonoscopy for recurrent c. diff

Conditions: Enterocolitis Clostridium Difficile Recurrent

Summary: delivery of fmt by upper route, including gastroscopy, nasogastric/ nasojejunal tube, and lower route, including retention enema, sigmoidoscopy, or colonoscopy have all been utilized successfully. endoscopic delivery requires significant health care utilization and associated cost. therefore, it is extremely desirable if fmt can be infused by a non invasive modality, which would significantly reduce patient discomfort, procedure related risks and health care costs, while offering similar efficacy to colonoscopic delivery in the range of 90%.

patients with minimum 3 episodes of clostridium difficile within 6 months are randomized 1:1 to received fmt by either colonoscopy or capsules. pts are assessed at 1 week, 2 weeks, 1 mon, 3 mon, 6 mon and 1 year post fmt. stool, urine and blood samples are collected. medical cost for previous treatment is collected as well at pt perspective and qol.

Eligibility criteria:
inclusion criteria: 1. age \> 18 and \< 90 years at the time of screening. 2. diagnosis of at least 3 episodes of recurrent cdi, with each episode defined as presence of diarrhea (\> 3 unformed stools/24 hours) associate with positive stool clostridium difficle toxin, occurring within 3 months of each other. 3. cdi infection under symptomatic control with \< 3 loose/unformed bm's per 24 h period for at least 2 consecutive days before procedure. 4. those with ability to provide informed consent. exclusion criteria: 1. those with complicated cdi, defined as white blood cell\>35 or \<0.5 x 109/l, significant abdominal pain and distension with evidence of toxic megacolon or pseudomembranous colitis, hypotension defined as systolic blood pressure \< 90 mmhg unresponsive to fluid resuscitation, end organ failure, or requiring intensive care unit admission. 2. those with chronic diarrheal illness, such as irritable bowel syndrome or inflammatory bowel disease unless they are in remission for at least 3 months prior to enrollment.
effect of omega 3 fatty acids on vascular function

Conditions: Previous Myocardial Infarction

Summary: the mechanisms through which omega-3 fatty acids reduce adverse cardiac events remain uncertain. the aim of the study was to investigate the effect of omega-3 fatty acid supplementation on endothelial vasomotor function, endogenous fibrinolysis, and platelet and monocyte activation in patients with coronary heart disease.

twenty patients with a previous myocardial infarction were recruited into a randomised, double-blind, placebo-controlled, crossover trial of omega-3 fatty acid supplementation (2g/day for 6-weeks). peripheral blood was taken for analysis of platelet and monocyte activation, and forearm blood flow was assessed in a subset of 12 patients during intrabrachial infusions of acetylcholine, substance p and sodium nitroprusside. stimulated plasma tissue plasminogen activator (t-pa) concentrations were measured during substance p infusion.

Eligibility criteria:
inclusion criteria: • myocardial infarction at least 3 months previously. exclusion criteria: * dietary fish allergy or intolerance * women of child bearing potential * malignant arrhythmias * renal or hepatic failure * severe or significant co-morbidity * previous history of blood dyscrasia * unable to tolerate the supine position * lack of informed consent * blood donation within last 3 months
surgical vs. medical treatment of urge urinary incontinence in women

Conditions: Urge Urinary Incontinence

Summary: the purpose of this study is to determine if pelvic surgery can improve urge urinary incontinence in women more than standard medical treatment.

urge urinary incontinence affects 30% of postmenopausal women. the etiology is unknown therefore treatment is symptomatic. for that purpose the nerval stimulation of the bladder muscle is interfered by several drugs, e.g. solifenacin. we observed that the surgical repair of critical pelvic structures, i.e. the uteri-sacral ligaments (usl) can restore continence in a considerable number of patients. in this study the surgical treatment is compared with the solifenacin treatment. according to outcome after three months patients who are still incontinent are referred to the opposite treatment group. outcome will be differentiated in cure (primary aim) and improvement of symptoms (secondary aim).

Eligibility criteria:
inclusion criteria: * urge urinary incontinence exclusion criteria: * stress urinary incontinence * cancer disease of the females genital tract * pregnancy * neurologic/psychological reasons for incontinence * body weight \>100kg * previous urogynecological surgery (tvt) * syndrome of dry overactive bladder (\>20 micturitions within 24 hours)

Keywords: surgery, solifenacin, urge urinary incontinence
pharmacokinetics and safety of hcp1303 and co-administration of hgp1201, hip1402 in healthy male volunteers

Conditions: Erectile Dysfunction; Prostatic Hyperplasia

Summary: to investigate the pharmacokinetic properties and safety after administration of hcp1303 and co-administration of hgp1201, hip1402 in healthy male volunteers

the purpose of this study is to investigate the pharmacokinetic properties and safety after administration of hcp1303 and co-administration of hgp1201, hip1402 in healthy male volunteers

Eligibility criteria:
inclusion criteria: 1. healthy male volunteer, age 20\~55 years 2. the result of body mass index(bmi) is not less than 19 kg/m2 , no more than 27 kg/m2 3. subject who has the ability to comprehend the study objectives, contents and the property of the study drug before participating in the trial 4. subject who has the ability and willingness to participate the whole period of trial exclusion criteria: 1. presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in kidney, liver, cardiovascular system, respiratory system, endocrine system, or neuropsychiatric system. 2. history of relevant drug allergies or clinically significant hypersensitivity reaction. 3. glomerular filtration rate is under 60ml/min which is calculated by serum creatinine value. 4. liver enzyme (ast, alt) level exceeds the maximum normal range more than one and a half times. 5. sbp: lower than 90mmhg or higher than 150mmhg, dbp: lower thatn 60mmhg or higher than 100mmhg 6. subjects who judged ineligible by the investigator.
effect of liraglutide on pulsatile insulin secretion in subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe. the aim of this trial is to assess the effect of nnc 90-1170 (liraglutide) on pulsatile insulin secretion and insulin secretion after a standard meal in subjects with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes, either newly diagnosed with at least two months of diet treatment, or in current oha (oral hypoglycaemic agent) treatment with stable dose for at least six months * bmi (body mass index) between 24 and 35 kg/m\^2 (both inclusive) * fasting plasma glucose between 6 and 15 mmol/l (both inclusive) * anti-gad (glutamic acid decarboxylase) negative exclusion criteria: * known or suspected allergy to trial product or related products * receipt of any investigational drug within three months prior to this trial * recurrent severe hypoglycaemia as judged by the investigator * cardiac disease or any clinically significant abnormal ecg (electrocardiogram) * use of any drug (except oral hypoglycaemic agents (ohas)) which in the investigator's opinion could interfere * with the blood glucose level (i.e., insulin, systemic corticosteroids, thiazides) * liver or renal disease
virtual reality distraction during phlebotomy in children

Conditions: Pain, Acute; Child, Only; Anxiety and Fear

Summary: this randomized controlled study was conducted to evaluate the effect of distraction methods using virtual reality on the emotional appearance, pain, fear, and anxiety associated with the procedure during phlebotomy in children aged 6-12 in a private blood collection unit.

the data of the study was collected with socio-demographic data collection form, emotional appearance scale for children, facial expression rating scale, child anxiety scale-state, and child fear scale. demographic data and mean scores obtained from the scales were compared between the virtual reality groups, and the control group.

Eligibility criteria:
inclusion criteria: * the child agrees to participate in the study voluntarily. * the parent agrees to participate in the study voluntarily. * obtaining consent forms from the child and parent exclusion criteria: * the child has a physical and psychological deficit that will prevent him from wearing the glasses that will be placed on his head to watch virtual reality. * having fever (\>37.5c) and severe dehydration * the patient did not take analgesics before the intervention

Keywords: phlebotomy virtual reality